The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| COV | -44.31% | +17.56% | +3.29% | -44% |
| S&P | +14.39% | +76.41% | +12.02% | +523% |
Covalon Technologies Ltd. engages in the research, development, manufacturing, and marketing of patent-protected medical products. It focuses on the wound care, infection management, and surgical procedures. The firm sells its products under the brand name Covalon. Its products categories include advanced wound care, vascular access, perioperative care, and urology. The company was founded on April 28, 2004 and is headquartered in Mississauga, Canada.
No news articles found for Covalon Technologies.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $8.69M | -2.0% |
| Gross Profit | $4.24M | -17.7% |
| Gross Margin | 48.76% | -9.3% |
| Market Cap | $53.74M | -34.2% |
| Net Income | $358.34K | -41.5% |
| EBITDA | $493.99K | -46.1% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $17.37M | 3.7% |
| Accounts Receivable | $5.84M | 60.2% |
| Inventory | 7.4 | -3.8% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $1.63M | 440.0% |
| Short Term Debt | $627.26K | 4.5% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 6.06% | -3.4% |
| Return On Invested Capital | -22.84% | 14.2% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$781.21K | -137.1% |
| Operating Free Cash Flow | -$667.21K | -131.4% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Earnings | 17.63 | 15.71 | 28.44 | 27.96 | -11.69% |
| Price to Book | 3.45 | 1.84 | 1.97 | 1.81 | -49.12% |
| Price to Sales | 2.63 | 1.82 | 2.03 | 1.75 | -40.42% |
| Price to Tangible Book Value | 3.70 | 1.93 | 2.07 | 1.90 | -50.30% |
| Price to Free Cash Flow TTM | 28.69 | 12.49 | 14.79 | 35.00 | 21.36% |
| Enterprise Value to EBITDA | 47.35 | 85.78 | 365.42 | 85.96 | 3.74% |
| Free Cash Flow Yield | 3.5% | 8.0% | 6.8% | 2.9% | -17.60% |
| Return on Equity | 19.6% | 14.5% | 9.0% | 7.1% | -38.71% |
| Total Debt | $784.67K | $609.46K | $1.28M | $2.25M | 149.95% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
